Open Leukemia Clinical Trials

Leukemia Studies Currently Recruiting Participants at the SimmonsCooper Cancer Research Center at Southern Illinois University School of Medicine

Protocol Title		Study #	Study Group
AML Previously Untreated
A Phase II Study of Lenalidomide (REVLIMID, NSC-703831) for Previously Untreated Non-M3, Deletion 5Q Acute Myeloid Leukemia (AML) in Patients Age 60 or Older Who Decline Remission Induction Chemotherapy		SWOG S0605	CICCOP
A Phase II Trial of Azacitidine (NSC-102816) Plus Gemtuzumab Ozogamicin as Induction and Post-Remission Therapy in Patients of Age 60 and Older With Previously Untreated Non-M3 Acute Myeloid Leukemia		SWOG S0703	CICCOP
A Phase III Randomized Trial of Gemtuzumab Ozogamicin (Mylotarg) Combined With Conventional Chemotherapy for De Novo Acute Myeloid Leukemia (AML) in Children, Adolescents, and Young Adults		COG AAML0531	SIU COG
AML in 1^st or 2^nd Remission
A Phase III Randomized Study of Farnesyl Transferase Inhibitor R115777 in Acute Myeloid Leukemia (AML) Patients in Second or Subsequent Remission or in Remission After Primary Induction Failure		ECOG E2902	CICCOP
APL
A Randomized Trial of Maintenance Versus Observation for Patients With Previously Untreated Low and Intermediate Risk Acute Promyelocytic Leukemia (APL), Phase III		SWOG S0521	CICCOP
CLL Previously Untreated
A Randomized Phase II Study of Three Fludarabine / Antibody Combinations for Patients With Symptomatic, Previously Untreated Chronic Lymphocytic Leukemia		ECOG/ CALGB 10404	CICCOP
ALL Newly Diagnosed
Intensified Methotrexate, Nelarabine (Compound 506U78; IND #52611) and Augmented BFM Therapy for Children and Young Adults With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia	COG AALL0434		SIU COG
High Risk B-Precursor Acute Lymphoblastic Leukemia	COG AALL0232		SIU COG
A Feasibility Pilot and Phase 2 Study Of Chemoimmunotherapy With Epratuzumab for Children With Relapsed CD22-Positive Acute Lymphoblastic Leukemia	COG ADVL04P2		SIU COG
ALL Relapsed
Treatment of Isolated Extramedullary Relapse From Acute Lymphoblastic Leukemia (ALL) (Initial CR1≥ 18 Months)	COG AALL02P2		SIU COG
Intensive Treatment for Intermediate-Risk Relapse of Childhood B-Precursor Acute Lymphoblastic Leukemia (ALL): A Randomized Trial of Vincristine Strategies	COG AALL0433		SIU COG
A Children's Oncology Group Protocol for Collecting and Banking Relapsed Acute Lymphoblastic Leukemia Research Specimens	COGAALL05B1		SIU COG
Myelodysplastic Syndrome
A Randomized Phase II Trial of Azacitidine With or Without the Histone Deacetylase Inhibitor MS-275 for the Treatment of Myelodysplastic Syndrome, Chronic Myelomonocytic Leukemia (Dysplastic Type), and Acute Myeloid Leukemia With Multilineage Dysplasia	ECOG E1905		CICCOP
Relapsed AML
A Phase II Study of Idarubicin and Ara-C in Combination With Pravastatin for Relapsed Acute Myelogenous Leukemia (AML)	SWOG S0919		CICCOP

Although our objective is to provide an updated listing of available clinical trials please note that a listing here does not guarantee that a trial is open or available to any specific patient and that there may be additional trials available that are not listed. Complete information is only available from a treating physician.

Contact Information:

SimmonsCooper Cancer Institute Clinical Trials Office
Mail Code 9677 Fax (217) 545-6823

Kathy Robinson, PhD, Director of Clinical Trials
(217) 545-1946

Susan Klug, RN, OCN
(217) 545-7929

Jennifer Bekker RN, BSN
(217) 545-2219

SIU COG

Carol Peterson, RN, CCRP (217) 545-7377

SIU IM

Amanda Fogleman, B.A. (217) 545-0592

Cathy Naritoku, M.S., RD (217)545-8078

SIU Thoracic